
BLRX Valuation
BioLine RX Ltd
- Overview
- Forecast
- Valuation
- Earnings
BLRX Relative Valuation
BLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BLRX is overvalued; if below, it's undervalued.
Historical Valuation
BioLine RX Ltd (BLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 3.02 is considered Fairly compared with the five-year average of -1.47. The fair price of BioLine RX Ltd (BLRX) is between 1.85 to 4.27 according to relative valuation methord.
Relative Value
Fair Zone
1.85-4.27
Current Price:3.83
Fair
-2.55
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
BioLine RX Ltd. (BLRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.27. The thresholds are as follows: Strongly Undervalued below -3.76, Undervalued between -3.76 and -2.52, Fairly Valued between -0.02 and -2.52, Overvalued between -0.02 and 1.23, and Strongly Overvalued above 1.23. The current Forward EV/EBITDA of 0.00 falls within the Overvalued range.
-0.07
EV/EBIT
BioLine RX Ltd. (BLRX) has a current EV/EBIT of -0.07. The 5-year average EV/EBIT is -1.74. The thresholds are as follows: Strongly Undervalued below -4.52, Undervalued between -4.52 and -3.13, Fairly Valued between -0.35 and -3.13, Overvalued between -0.35 and 1.04, and Strongly Overvalued above 1.04. The current Forward EV/EBIT of -0.07 falls within the Overvalued range.
3.02
PS
BioLine RX Ltd. (BLRX) has a current PS of 3.02. The 5-year average PS is 12.86. The thresholds are as follows: Strongly Undervalued below -74.10, Undervalued between -74.10 and -30.62, Fairly Valued between 56.34 and -30.62, Overvalued between 56.34 and 99.82, and Strongly Overvalued above 99.82. The current Forward PS of 3.02 falls within the Historic Trend Line -Fairly Valued range.
-2.85
P/OCF
BioLine RX Ltd. (BLRX) has a current P/OCF of -2.85. The 5-year average P/OCF is -0.46. The thresholds are as follows: Strongly Undervalued below -2.31, Undervalued between -2.31 and -1.39, Fairly Valued between 0.46 and -1.39, Overvalued between 0.46 and 1.38, and Strongly Overvalued above 1.38. The current Forward P/OCF of -2.85 falls within the Strongly Undervalued range.
1.83
P/FCF
BioLine RX Ltd. (BLRX) has a current P/FCF of 1.83. The 5-year average P/FCF is 0.02. The thresholds are as follows: Strongly Undervalued below -1.94, Undervalued between -1.94 and -0.96, Fairly Valued between 1.01 and -0.96, Overvalued between 1.01 and 1.99, and Strongly Overvalued above 1.99. The current Forward P/FCF of 1.83 falls within the Overvalued range.
BioLine RX Ltd (BLRX) has a current Price-to-Book (P/B) ratio of 472.79. Compared to its 3-year average P/B ratio of 80.00 , the current P/B ratio is approximately 491.00% higher. Relative to its 5-year average P/B ratio of 48.67, the current P/B ratio is about 871.49% higher. BioLine RX Ltd (BLRX) has a Forward Free Cash Flow (FCF) yield of approximately -133.27%. Compared to its 3-year average FCF yield of -92.05%, the current FCF yield is approximately 44.78% lower. Relative to its 5-year average FCF yield of -67.24% , the current FCF yield is about 98.21% lower.
472.79
P/B
Median3y
80.00
Median5y
48.67
-133.27
FCF Yield
Median3y
-92.05
Median5y
-67.24
Competitors Valuation Multiple
The average P/S ratio for BLRX's competitors is 1.00, providing a benchmark for relative valuation. BioLine RX Ltd Corp (BLRX) exhibits a P/S ratio of 3.02, which is 202.92% above the industry average. Given its robust revenue growth of -94.36%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BLRX decreased by 85.20% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.74 to -841.46.
The secondary factor is the Revenue Growth, contributed -94.36%to the performance.
Overall, the performance of BLRX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

DC
Dakota Gold Corp
3.960
USD
-0.75%

GASS
StealthGas Inc
7.100
USD
+3.50%

OVLY
Oak Valley Bancorp
27.610
USD
-0.14%

FXNC
First National Corp
22.210
USD
-0.22%

MFIN
Medallion Financial Corp
10.240
USD
+1.09%

SMID
Smith-Midland Corp
42.560
USD
+0.92%

SKIN
Beauty Health Co
2.190
USD
+0.46%

BLFY
Blue Foundry Bancorp
8.990
USD
+0.78%

ODV
Osisko Development Corp
2.550
USD
+0.39%

FVCB
FVCBankcorp Inc
12.840
USD
+0.08%
FAQ

Is BioLine RX Ltd (BLRX) currently overvalued or undervalued?
BioLine RX Ltd (BLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 3.02 is considered Fairly compared with the five-year average of -1.47. The fair price of BioLine RX Ltd (BLRX) is between 1.85 to 4.27 according to relative valuation methord.

What is BioLine RX Ltd (BLRX) fair value?

How does BLRX's valuation metrics compare to the industry average?

What is the current P/B ratio for BioLine RX Ltd (BLRX) as of Aug 19 2025?

What is the current FCF Yield for BioLine RX Ltd (BLRX) as of Aug 19 2025?

What is the current Forward P/E ratio for BioLine RX Ltd (BLRX) as of Aug 19 2025?
